Kornimate/medical-research-clean huggingface dataset:
effect of an allergen vaccine in patients with allergic rhino-conjunctivitis and asthma due to house dust mite allergy

Conditions: Perennial Allergic Rhinoconjunctivitis; Allergic Asthma

Summary: the purpose of the study is to test the safety, tolerability, immunogenicity and clinical efficacy of the combination treatment allqbg10 in patients with rhino-conjunctivitis and asthma due to house dust mite allergy in a single-center, open-label setting.


Eligibility criteria:
inclusion criteria: * mild to moderate perennial allergic rhinoconjunctivitis due to sensitization against house dust mites * mild asthma * females only if non-reproductive or agree to practice an effective and accepted method of contraception exclusion criteria: * relevant cardiovascular, renal, pulmonary or endocrine disease * history of autoimmune disease * severe allergies * history of active infectious disease * current diagnosis or history of malignancy * relevant neurological or psychiatric disorder * pregnancy or lactation * history of alcohol abuse or other recreational drugs * use of an investigational drug within three month before enrolment * blood donation within 30 days before enrolment
a study of shr-a1921 with or without carboplatin in subjects with ovarian cancer

Conditions: Ovarian Cancer

Summary: this is an open-label, randomized, controlled, two-part study to evaluate the safety and efficacy of shr-a1921 with or without carboplatin verus investigator's choice of platinum-based doublet chemotherapy in subjects with recurrent epithelial ovarian cancer.


Eligibility criteria:
inclusion criteria: 1. voluntary participation and written informed consent. 2. be able to provide fresh or archived tumour tissue. 3. pathologically diagnosed epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer. 4. at least one measurable lesion according to recist v1.1. 5. eastern cooperative oncology group (ecog) score: 0-1. 6. with a life expectancy ≥ 12 weeks. 7. adequate bone marrow reserve and organ function. exclusion criteria: 1. uncontrolled pleural effusion, pericardial effusion, or abdominal effusion with clinical symptoms. 2. previous or co-existing malignancies. 3. has a history of non-infectious ild/pneumonitis that required steroids, or has current ild/pneumonitis; 4. subjects with active hepatitis b or active hepatitis c; 5. subjects who have received systemic anti-tumor treatments 4 weeks prior to the initiation of the study treatment. 6. subjects who have been treated with top1 inhibitors, trop-2 adc or adcs with top1 inhibitors as payload. 7. has unresolved ctcae ≥grade 2 toxicities from previous anticancer therapy.
teamwork makes the dream work

Conditions: HIV Infections; Inpatient Facility Diagnoses

Summary: exploring the effect of team-based artas intervention in an inpatient setting on hiv linkage to care and hospital readmission rates.


Eligibility criteria:
inclusion criteria: * 18 years of age or greater * newly diagnosed hiv * known diagnosis of hiv not on art within 30 days of admission * known hiv and not virally suppressed based on interview * known hiv and has not been under the care of an hiv specialist within the past 6 months exclusion criteria: * all three criteria must be present for exclusion: * virally suppressed * actively taking art * are under active care of an hiv specialist within the last 6 months * less than 18 years of age (stand alone exclusion)

Keywords: hiv, linkage to care, hospital readmission
transcutaneous vagus nerve stimulation for generalized anxiety disorder

Conditions: Generalized Anxiety Disorder

Summary: this is a randomized, double-blind, parallel-controlled study of patients with generalized anxiety disorder, who will be randomly assigned to either drug-combined transcutaneous vagus nerve stimulation (tvns) group or drug-combined sham-stimulation group for a period of 4 weeks of treatment.scale assessments will be performed at baseline, week 1, week 2, week 3, and week 4 of treatment, and brain function monitoring as well as laboratory tests will be performed at baseline and at the end of treatment, respectively.the aim of this study is to investigate the efficacy of medication combined with tvns and the possible mechanisms of tvns in the treatment of anxiety.


Eligibility criteria:
inclusion criteria: * meeting dsm-5 diagnostic criteria for generalized anxiety disorder; * having a first episode of generalized anxiety disorder or not having used an anxiolytic, antidepressant, antipsychotic, or anticonvulsant medication in the last 1 month. * having a hamilton anxiety scale (hama) score of more than 14 and a hamilton depression scale (hamd-17) score of less than 17. exclusion criteria: * having organic brain lesions (e.g., cerebral hemorrhage, massive cerebral infarction, encephalitis, epilepsy); cardiac qtc interval \> 450ms; * current or previous diagnosis of other major diseases (e.g., coronary heart disease, pulmonary heart disease, etc.) * currently or previously diagnosed with a mental disorder other than anxiety disorder (except for insomnia disorder); * those who are participating or have participated in vagus nerve stimulation therapy; those who are participating in transcranial magnetic stimulation or transcranial direct current therapy; * pregnant, breastfeeding, or planning to become pregnant during the trial; * refusing to sign the informed consent form.
impact of systemic corticosteroid therapy on lens transparency and quantification of lens autofluorescence.

Conditions: Patients With Systemic Inflammatory Diseases Receiving for the First Time a Protracted General Corticostroid Therapy

Summary: corticosteroid therapy is usually regarded as a risk factor for the development of posterior subcapsular cataracts but prospective studies on this topic and accurate assessment of this potential adverse effect are lacking. we will evaluate changes of lens transparency after administration of systemic corticosteroid therapy for at least one year with scheimpflug photography and quantification of lens autofluorescence.

corticosteroid therapy is usually regarded as a risk factor for the development of posterior subcapsular cataracts but prospective studies on this topic and accurate assessment of this potential adverse effect are lacking. we will evaluate changes of lens transparency after administration of systemic corticosteroid therapy for at least one year with scheimpflug photography and quantification of lens autofluorescence.

Eligibility criteria:
inclusion criteria: * patient who starts a treatment with prednisone, prednisolone or methylprednisolone for an expected time of one year at least, with normal lens autofluorescence at inclusion. exclusion criteria: * previous cataracts and abnormal increase of lens autofluorescence considering age * previous elevation of intraocular pressure * progressive inflammatory or non inflammatory ocular disease * eye drop except artificial tears * insulin dependent and non insulin dependent diabetes * atopic dermatitis * previous protracted corticosteroid therapy * drugs known to be associated with an increased risk of cataract

Keywords: cataracts corticosteroids scheimpflug lens autofluorescence
ultrasonographic muscles and fascia measurement with myofascial pain syndrome

Conditions: Myofascial Pain Syndrome

Summary: pathologies in the trapezius muscle and rhomboid muscle are important in the course and treatment of the disease in patients with myofascial pain syndrome.

in this study, the role of the thickness of these muscles and the shift during movement in the activity and diagnosis of the disease in myofascial pain syndrome will be investigated.

Eligibility criteria:
inclusion criteria: * 18-65 years old * myofascial pain syndrome exclusion criteria: * cervical radiculopathy * fibromyalgia * shoulder joint disease, * peripheral and central nervous system disease * polyneuropathy, * inflammatory rheumatic disease, * malignancy
the impact of ai-based fundus imaging on blood glucose control and fundus examination completion rates in outpatient diabetic patients

Conditions: Diabetes

Summary: this study aims to evaluate the impact of ai-based fundus imaging on blood glucose control and fundus examination completion rates in diabetic patients by comparing outcomes between those who undergo ai fundus imaging and those who do not. the study is designed as a parallel randomized controlled trial (rct). using a random number table, 200 diabetic patients visiting the department of endocrinology at sichuan provincial people's hospital between december 2024 and december 2025 will be equally divided into two groups: an intervention group and a control group. each group will consist of 100 patients, assigned unique random numbers. the intervention group will undergo ai-based fundus imaging once, with the imaging process taking approximately 5 minutes. the control group will receive standard eye health education without ai fundus imaging. the primary outcomes, including blood glucose control, systemic indicators, and fundus examination completion rates, will be assessed and compared between the two groups at 3-month and 6-month follow-ups. this study seeks to determine the value of ai-based fundus imaging in improving diabetes management and complication prevention in diabetic patients.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years. * diagnosis of type 2 diabetes mellitus. * patients with a glycated hemoglobin (hba1c) level \> 7%. * ability to comply with all required examinations and provide signed informed consent. exclusion criteria: * no previous diabetic fundus examination. * no known diabetic retinopathy. * absence of other ocular diseases that could lead to retinopathy. * subjects from whom clear fundus photographs could not be obtained. * patients with comorbid malignant tumors or severe cardiovascular diseases. * patients anticipated to have difficulties with follow-up or those residing in other provinces.
modulation of tissue sodium in hemodialysis patients

Conditions: Chronic Kidney Disease Requiring Chronic Dialysis

Summary: salt (nacl) intake is implicated in causing hypertension and cardiovascular disease, the commonest cause of death worldwide. the investigators recently established that na+ is stored in tissues, bound to glycosaminoglycans (gags) in skin and muscle. the resulting local hypertonicity leads to immune cell-driven induction of local tissue electrolyte clearance via modulation of cutaneous lymph capillary density. to visualize these complex processes in man directly, the investigators established na+ magnetic resonance imaging (23na-mri) and investigated na+ stores in hemodialysis (hd) patients. hemodialysis patients were sodium-"overloaded" and hd treatment lowered tissue na+ stores in this study. the observed effects were highly variable and independent of na+ or water removal from the body during a dialysis session. tissue na+ mobilization correlated with circulating vascular endothelial growth factor-c (vegf-c). the investigators believe that excessive na+ storage is a reversible condition and therefore susceptible for therapeutic interventions. the investigators hypothesize that lowering dialysate na+ concentration may favorably affect accelerated tissue na+ accumulation in hemodialysis patients. besides, improved tissue na+ storage, osmostress-induced as well as pro-inflammatory immune cell response should be affected by such a revised dialysis management.

to evaluate effects of moderate reduction of dialysate na+ concentration on tissue na+ content the investigators intend to recruit 40 hemodialysis patients, who will be offered a therapeutic change of their dialysate na+ concentration. after detection of tissue na+ content using 23na-mri technique, the applied dialysate \[na+\] will be initially increased stepwise by 2 mmol/l per week from 138 to 142 mmol/l and maintained for a period of 5 weeks. after another 23na-mri measurement, dialysate \[na+\] will then be lowered stepwise by 1-2 mmol/l per week to a minimum of 135 mmol/l, which will be also maintained for a period of 5 weeks followed by a final 23na-mri assessment. hypothesis: reduction of dialysate na+ concentration will decrease tissue sodium storage. additionally, the investigators will assess changes in body fluid distribution by bioimpedance spectroscopy. furthermore, vascular compliance in response to the modulation of dialysate \[na+\] and its correlation with tissue na+ will be assessed. to investigate the immune response to tissue na+ accumulation, the osmostress-induced as well as pro-inflammatory immune cell response of isolated monocytes will be quantified.

Eligibility criteria:
inclusion criteria: * chronic kidney disease stage 5d, hemodialysis performed for at least 6 months, three times hemodialysis per week, signed informed consent exclusion criteria: * pregnancy, severe heart failure (nyha iii - iv), severe liver disease (child c), acute infection, pacemaker or other non-mri suitable conditions, hyponatremia \< 132 mmol/l

Keywords: 23na mri
effect of meal texture on glucose-metabolism and gut hormone response after bariatric surgery

Conditions: Glucose Metabolism Disorders; Obesity; Sleeve Gastrectomy; Gastric Bypass; Gut Hormones

Summary: the investigators want to evaluate the difference in glucose metabolism and intestinal hormonal response after a liquid meal versus a solid meal in patients after bariatric surgery.


Eligibility criteria:
inclusion criteria: * age \> 18 years * rygb or sg operation \> 12 months prior to inclusion * weight stable (± 3 kg during the last month) * hba1c \< 48 mmol/mol before surgery, and no history of diabetes * hba1c \< 48 mmol/mol and fasting plasma glucose \< 6.1 mmol/l at inclusion exclusion criteria: * thyrotoxicosis or inadequately treated hypothyreosis * hemoglobin \< 6.5 mmol/l at inclusion * pregnancy or breast feeding * medication affecting the planned examinations
effect of modified complete decongestive therapy on lower limbs fibrosis post cellulitis

Conditions: Lower Limb Lymphedema; Fibrosis; Cellulitis of Leg

Summary: this study will be designed to investigate the therapeutic benefits of kinesio tape in combination to complete decongestive therapy on limb volume , skin fibrosis, functional capacity ,ankle range of motion, lymphedema associated symptoms (pain, tightness, heaviness and hardness) and quality of life in patients with lower limbs fibrosis post cellulitis ,as well as finding out a physical therapy approach that has positive effect in treatment and care such cases which would enhance the physical therapy field.

lymphedema patient need a rehabilitative intervention in two phases : decongestion phase to reduce edema volume , improve the skin extensibility and provide him a better quality of life, followed by the maintenance phase to keep the outcomes. when we use the kinesio tape in addition to the complete decongestive therapy, the patient will experience a better improvement in the edema volume and the skin extensibility within a shorter period of time , a lesser number of sessions and a lower cost. so, the patient will have a better quality of life and could be a productive person in the society.

Eligibility criteria:
inclusion criteria: the patient will be according the following criteria:- 1. males and females with lower limb lymphedema stage 2. 2. age will range from45 to 55years old. 3. bmi \<40 (kg/m2). 4. all patients will be clinically and medically stable when attending the study. 5. patients free from any acute conditions. 6. post cellulitis for at least 2 weeks. exclusion criteria: 1. unstable cardiovascular problems. 2. altered mental status or poor cognition. 3. lower limb ischemia (abi ≤0.8). 4. lower limb lymphedema stage 3\&4. 5. acute deep venous thrombosis. 6. any acute infection. 7. patients with orthopedic or neurological limitations to exercise. 8. any lower limb acute ulcer or arterial wounds.

Keywords: lymphedema complete decongestive therapy kinesio tape
impact of endostar combined with chemotherapy on the angiogenesis of advanced non-small cell lung cancer (nsclc)

Conditions: Lung Neoplasms

Summary: to study the impact of endostar combined with docetaxel and cisplatin on the angiogenesis of non-small cell lung cancer, patients will be randomly assigned to the group one (endostar combined with docetaxel and cisplatin) and group two (docetaxel and cisplatin). * the serum concentrations of endostatin,vegf and bfgf are determined. * blood circulating endothelial cells (cecs) and circulating hematopoietic progenitor cells (cpcs) will be measured by flow cytometer. * statistical analysis will be applied to study the relationship between the levels of endostatin, vegf, bfgf, cecs and cpcs and the clinical outcomes such as objective response rate(ort), time to progression (ttp), mean survival time(mst), toxicity and quality of life (qol).

to study the impact of endostar combined with docetaxel and cisplatin on the angiogenesis of non-small cell lung cancer,patients will be randomly assigned to the experimental group(endostar combined with docetaxel and cisplatin) and the control group (docetaxel and cisplatin). * the serum concentrations of endostatin,vegf and bfgf are determined. * blood circulating endothelial cells (cecs) and circulating hematopoietic progenitor cells (cpcs) will be measured by flow cytometer. * the clinical parameters such as objective response rate (ort),time to progression(ttp) and mean survival time(mst) will be collected according to the who criteria. * the toxicity will be recorded according to the nci-ctc v3.0. * the quality of life was self-assessed using the european organisation for research and treatment of cancer (eortc) qlq c-30 questionnaire. * statistical analysis will be applied to study the relationship between the levels of endostatin,vegf,bfgf,cecs and cpcs and the clinical outcomes such as ort, ttp, mst, toxicity and qol.

Eligibility criteria:
inclusion criteria: * clinical diagnosis of advanced or metastatic nsclc (confirmed histologically, with a tumor that was measurable by clinical and/or radiologic examination. * have an eastern cooperative oncology group performance status 0 to 2. * adequate renal, cardiac, hepatic, and hematologic function as indicated by the following parameters: absolute neutrophil count 2 x the ninth power of ten/l, thrombocytes 100 x the ninth power of ten/l, hemoglobin 10 g/dl, total bilirubin 1.25x the upper limit of normal range (uln), alt and ast 1.5x uln, alkaline phosphatase 5x uln, creatinine 1.15x uln. exclusion criteria: * known brain metastases or secondary neoplasia. * myocardial insufficiency or myocardial infarction within the preceding 6 months. * severe renal or hepatic insufficiency. * pre-existing motor or sensor neurotoxicity who grade 2. * severe psychologic disease. * active infection, or other condition that could compromise protocol compliance. * simultaneous administration of other antineoplastic medications. * clinically significant hemoptysis. * pregnancy and/or lactation.

Keywords: lung neoplasms endostatins vascular endothelial growth factors fibroblast growth factors survival rate
time restricted eating in haematological malignancies

Conditions: Cancer; Chronic Lymphocytic Leukemia

Summary: the goal of this clinical trial is to learn if time restricted eating (tre), a form of intermittent fasting, can impact health outcomes in patients with chronic lymphocytic leukemia (cll). the main questions it aims to answer are: * in patients with cll, is there a decrease or stabilization in cancer cell counts associated with tre compared to baseline? * is there a decrease in immune cell autophagy (a cellular recycling process) activity associated with tre compared to baseline? * does adherence to a tre regimen improve patient experience and quality of life? immune cell autophagy activity in cancer patients will be compared to a subset of control participants without cancer. participants will: * adhere to a 16/8 fasting regimen, which involves eating as normal for 8 hours per day and fasting (only consuming water, black coffee or black tea) for the remaining 16 hours. they will follow this intervention for their choice of either 3 or 6 months. * complete monthly blood collections * complete weekly journal entries to record weekly weight and timing of first and last daily meals * complete weekly safety check-ins with a study team member for the first 4 weeks of the study and then bi-weekly thereafter * complete 3 quality of life questionnaires * provide 3 stool samples (optional component of study) * complete an end of study interview (optional component of study)


Eligibility criteria:
inclusion criteria: experimental participants: * diagnosis of cll or sll, age 18-85 * peripheral blood lymphocytes \>20 x 10\^9/l * hemoglobin \>90g/l * platelets ˃90 x 10\^9/l * bmi of \>=20kg/m2 * ecog performance status \>=2 * not following any form of if for 4 months prior to study control participants: * absence of cancer diagnosis (active or historical) * age 18-85, peripheral blood lymphocytes \<5 x10\^9/l * bmi of \>=20kg/m2 * ecog performance status \>=2 * not following any form of if for 4 months prior to study exclusion criteria: experimental and control participants: * unable to give consent * on medications required to be taken with food during the fasting window * pregnant or breastfeeding * diabetes mellitus * bmi drop to \< 18.5kg/m2 at any time during study * anti-lymphoma therapy within the past 3 months * expected to initiate anti-lymphoma therapy within the next 3 months * unable to fast due to a digestive system disorder * \> 85 years of age (due to frailty, increased risk of infection, and burden of additional blood collections)

Keywords: time restricted eating intermittent fasting diet cancer chronic lymphocytic leukemia autophagy microbiome inflammation epigenetics